放射免疫与化学发光免疫检测对甲状腺肿瘤的诊断价值比较

doi:10.3969/j.issn.1671-7171.2025.08.026

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1253 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To compare the diagnostic value of radioimmunoassay and chemiluminescence immunoassay in thyroid tumors.【Methods】 A total of 76 patients with suspected of having thyroid tumors were included in the study. The pathological diagnosis was served as the gold standard. The levels of thyroglobulin detected by both radioimmunoassay and chemiluminescence immunoassay were compared. The diagnostic performance of the two methods was evaluated using receiver operating characteristic (ROC) curve analysis.【Results】 The number of thyroglobulin-positive cases, thyroglobulin antibody levels, and thyroglobulin levels detected by chemiluminescence immunoassay were all significantly higher than those detected by radioimmunoassay (P<0.05). The diagnostic concordance rate between chemiluminescence immunoassay and pathological diagnosis was 92.11% (70/76), which was significantly higher than that of radioimmunoassay (76.32%, 58/76); And the difference was statistically significant (P<0.05). ROC curve analysis showed that the area under the curve (AUC), sensitivity, and specificity of chemiluminescence immunoassay were significantly higher than those of radioimmunoassay (P<0.05).【Conclusion】 Compared to radioimmunoassay, chemiluminescence immunoassay has higher clinical value and better diagnostic performance in the diagnosis of thyroid tumors, providing more reliable evidence for clinical diagnosis and treatment.

Key words： Thyroid Neoplasms Radioimmunoassay Immunoassay Luminescent Measurements

Received: 26 March 2025

PACS:

R736.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHANG Hui
	SHI Zhipeng
	DONG Shuxiao

Cite this article:

CHANG Hui,SHI Zhipeng,DONG Shuxiao. Comparison of the Diagnostic Value of Radioimmunoassay and Chemiluminescence Immunoassay in Thyroid Tumors[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(8): 1385-1387.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.08.026 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I8/1385

[1] 戈月平,周玲玲甲状腺肿瘤的影响因素研究进展[J].检验医学与临床,2014,11(4):516-517.
[2] 温绍云. 化学发光免疫测定技术在甲状腺肿瘤检验中的价值探讨[J].中国现代药物应用,2021,15(10):125-127.
[3] 王丁泉. 放射免疫分析技术的发展现状与展望[J].标记免疫分析与临床,2012,19(4):249-251.
[4] SHRESTHA B,DUNN L.The declaration of helsinki on medical research involving human subjects: a review of seventh revision[J].J Nepal Health Res Counc,2020,17(4):548-552.
[5] 杨律,罗达良. 两种方法检测血浆甲状腺球蛋白的效果比较[J].中国基层医药,2013,20(17):2673-2675.
[6] 刘树利. 生化检验中化学发光免疫测定技术的应用观察[J].医药论坛杂志,2015,36(12):168-169.
[7] 李文坚,杜家敏,沈晓琼. 化学发光免疫测定技术诊断甲状腺肿瘤的临床应用价值研究[J].现代诊断与治疗,2023,34(5):660-662.
[8] 王旭. 甲状腺肿瘤患者免疫检验中使用化学发光免疫测定技术的临床价值研究[J].中国实用医药,2021,16(2):73-75.
[9] 袁兆林. 甲状腺肿瘤患者生化免疫检验中应用化学发光免疫测定技术的临床价值分析[J].国际医药卫生导报,2019,25(10):1633-1634.
[10] 宋玉庭,张萌萌,吴乃宝. 化学发光免疫分析和放射免疫分析测定血清CEA、CA-153结果的评价[J].中国实验诊断学,2010,14(5):766-767.
[11] EVANS C, LOTZ J, BHANDARI M, et al. Multi-center evaluation of the highly sensitive Abbott ARCHITECT and Alinity thyroglobulin chemiluminescent microparticle immunoassay[J].J Clin Lab Anal,2022,36(9):e24595.
[12] 郎华. 生化免疫检验中化学发光免疫测定技术对甲状腺肿瘤的诊断价值分析[J].中国现代药物应用,2021,15(24):105-107.
[13] 王堃,喻晶,雷旦生. 化学发光法和放射免疫法检测TPA的比较研究[J].中国卫生检验杂志,2015,25(6):846-847.